Avalon Pharmaceuticals


Avalon Pharmaceuticals Reviews

0 Reviews
0 Reviews

Recommend to a friend
Approve of CEO
(no image)
Andrew J. (Drew) Fromkin
0 Ratings

Avalon Pharmaceuticals Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.avalonrx.com
Headquarters Germantown, MD
Size 50 to 149 Employees
Founded Unknown
Type Subsidiary or Business Segment
Industry Biotech & Pharmaceuticals
Revenue $1 to $5 million (USD) per year

Avalon Pharmaceuticals doesn't mind if genes express themselves -- but they should know that anything they express can and will be used against them if they lead to cancer. The biopharmaceutical firm develops cancer therapeutics based on its AvalonRx platform, which identifies compounds that would be best suited to advance in clinical drug development. Lead product AVN944, an inhibitor of hematologic (leukemia, lymphoma, and myeloma) and solid tumor cancers, is an oral drug now in clinical trials. Avalon also has preclinical programs to develop inhibitors through... More

Work at Avalon Pharmaceuticals? Share Your Experiences

Avalon Pharmaceuticals

Click to Rate